Triple-negative breast cancers (TNBCs) represent 15–20% of breast carcinomas and are defined by the lack of expression of estrogen receptor (ER) and progesterone receptor (PR) and the lack of overexpression and/or amplification of human epidermal growth factor receptor 2 (HER2). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.